What the experts say about Histotype Px® Colorectal

  • “There is a high medical need to personalize treatment and avoid over- and undertreatment. I strongly believe that the use of Histotype Px in clinical decision-making has the potential to guide personalized cancer treatment decisions and [...] significantly improve patient outcomes and reduce health care costs […] representing a potential game-changing innovation for cancer patients."

    – Prof. Cornelis Verhoef, Surgical Oncologist and Chair Department of Surgical Oncology, Erasmus MC Cancer Institute

  • "DoMore Diagnostics is developing a ground-breaking digital biomarker that can predict the survival outcome of colorectal cancer patients and can guide personalized treatment decisions for each patient to avoid over- and undertreatment with chemotherapy."

    - Prof. Claus Lindbjerg Andersen, Head of the Colorectal Cancer Research Group, Director of the National Danish Circulating Tumor DNA Research Center, Aarhus University Hospital

  • "Post-surgery ctDNA may help identify patients not cured by surgery who may benefit from ACT, although false negative results remain a concern. This pilot study suggests that Histotype Px can improve the accuracy of ctDNA tests and reduce false negatives, confirming the potential clinical utility of Histotype Px in this setting."

    - Prof. Jeanine Roodhart, MD, PhD, Department of Oncology, University Medical Center Utrecht

  • "There is an urgent medical need to personalise cancer therapy and, in particular, to target adjuvant therapy to only those patients who will benefit from such treatment. [...] The use of Histotype Px will allow more informed treatment decisions that are tailored to the individual patient's tumour leading to improved patient outcomes."

    - Prof. Marco Novelli, Consultant Histopathologist and Professor of Gastrointestinal Pathology, UCL, London

  • “According to current US clinical guidelines most high-risk stage II and all stage III colon cancer patients are recommended ACT, however many patients have a low risk of recurrence and do not benefit from this toxic treatment. The pilot validation data [...] further supports the potential clinical utility of Histotype Px as a tool to guide treatment decisions to escalate or de-escalate ACT treatment."

    - Dr. Eric D. Miller, MD, PhD, Department of Pathology, Ohio State University Comprehensive Cancer Center

  • “One of the problems with chemotherapy is that we have to treat many patients to benefit few, but many patients experience serious and dangerous side effects, so if I had a means of better identifying patients that would truly benefit form chemotherapy, we would reduce the pain and burden of individual patients and reduce costs to the health care system.”

    – Dr David Kerr, Oncologist and Professor of Cancer Medicine, University of Oxford

  • "We need new and better biomarkers for colorectal cancer to provide more precise and personalized care. With such a tool, we hope to optimize treatment strategies, minimize side effects, and ultimately improve the lives of patients affected with this challenging disease."

    - Prof. Kjetil Søreide, MD, PhD, FRCS (Edin), FACS FEBS (hon), Consultant Surgeon and Leader of the Gastrointenstinal Translational Research Unit at Stavanger University Hospital and Professor of Surgery at University of Bergen

  • "There is currently a lack of reliable biomarkers to guide treatment decisions in colorectal cancer. DoMore Diagnostic’s digital biomarker Histotype Px Colorectal addresses a large unmet medical need and we are very excited about the potential utility of this tool to improve the treatment we can offer this patient population."

    - Dr. Mohamed-Amine Bani, Medical Biology and Pathology Department, Gustave Roussy Cancer Campus

Advancing Precision Oncology with AI-Powered Digital Pathology for Clinical Decision Support

DoMore Diagnostics is transforming cancer care with artificial intelligence. Our lead product, Histotype Px® Colorectal, leverages deep learning and digital pathology to predict patient outcomes and support more accurate, personalized treatment decisions in colorectal cancer (CRC).

The lack of reliable and affordable biomarkers to personalize treatment remains a major unsolved challenge in cancer, and in particular colorectal cancer (CRC). Surgery is the standard of care in stage II and stage III CRC, often followed by adjuvant chemotherapy (ACT) in a one-size-fits-all approach.

However, most patients are cured by surgery alone in this indication and ACT provides no benefit to the majority of patients (96-98% in stage II and 80% in stage III), only exposing them to short- and long-term side effects. A personalized approach to ACT is therefore needed to avoid overtreatment of low-risk patients with reduced quality of life and unnecessary healthcare costs, and also to avoid undertreatment of early-stage cancers who in fact are high risk.

The Histotype Px® Colorectal digital biomarker predicts the outcome for stage II and stage III CRC patients and can guide personalized treatment decisions for each patient identifying the patients who are likely to benefit from ACT and the patients who will do better without.

Video cover image by: Ketil Jordan

Why It Matters:

  • CRC is the 3rd most common and 2nd most deadly cancer worldwide

  • Selection of stage II/III patients receiving toxic adjuvant chemotherapy (ACT) is critical to optimize outcomes

  • Current tools do not offer the precision needed for optimal risk stratification

Our Solution:

Histotype Px® Colorectal* digital biomarker is an advanced deep neural network algorithm for determining recurrence and survival prognosis in colorectal cancer based on routine H&E-stained histology slides. The colorectal algorithm is robust and based on solid ground truth and extensive training and testing with in total 4500 patient samples, 90 million image tiles. The slides were prepared at several sites, scanned at two sites with two different scanners, to ensure that the test is robust and can be used in clinical practice.

Histotype Px® Colorectal is CE-IVDD marked.

*The early version of Histotype Px® Colorectal was named DoMore-V1-CRC (and misc. variations of this description) during development in the DoMore! Project. The CE-IVD certified product Histotype Px® Colorectal is an updated version.

Video cover image: Marian Seiergren

Key Features:

  • Digital biomarker enabling personalized cancer treatment

  • Accurate risk stratification

  • Rapid turnaround time

  • Seamless workflow integration

  • Complements and improves accuracy of ctDNA

Histotype Px® Colorectal Provides Distinct Risk Stratification to Personalize Treatment

- Large potential to reduce current chemotherapy overtreatment

Histotype Px® Colorectal indicated for stage II and III CRC

Source: Taieb et al. Cancer Treat Rev (2019); Norwegian Cancer Society

Cancer specific survival per risk group

Recurrence per risk group
- patients who did not receive adjuvant chemotherapy

Proven Clinical Impact: Data That Makes a Difference

Clinical Evidence

Scientific data on Histotype Px® Colorectal have been published in several journals. A landmark study in The Lancet Oncology showed that Histotype Px® Colorectal significantly improves prognostic accuracy when combined with TNM staging in QUASAR II trial:

  • Hazard Ratio: 9,47 (high vs. low risk)

  • Outcome: Identification of patients who may benefit from de-escalating ACT

  • Result: Reduced overtreatment and improved patient outcomes

Clinical Collaborations

DoMore Diagnostics is collaborating with leading cancer centers and KOLs in Europe, USA and Japan.

These partnerships explore:

  • Validation across diverse populations and treatment regimen

  • Combination with ctDNA

  • Enhanced decision support in ambiguous cases

Seamless Integration for Pathology Teams

Histotype Px® Colorectal is available on leading digital pathology platforms:

  • Sectra Amplifier Marketplace

  • PathAI’s AISight™

  • Proscia’s Concentriq® Dx

This ensures:

  • Fast and intuitive user experience

  • Easy integration with existing workflows

  • No formal training required

AI and digital pathology will revolutionize the way we treat cancer

CEO and Co-Founder Torbjørn Furuseth presents the company and our leading digital biomarker Histotype Px® Colorectal at the LSX Nordic Congress 2023.

Technology

DoMore Diagnostics is a pioneer in utilizing artificial intelligence to increase the prognostic and predictive value of cancer tissue biopsies. The company’s AI-powered digital biomarker is based on extensive research at top universities with deep learning in histology image analysis. These new methods have resulted in fully automated histotyping that provide objective and precise prognostic information about patient outcomes. This novel approach can guide selection of therapy to avoid over- and undertreatment of cancer patients. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, which is the fundament for precision medicine.

Video cover image by: Ketil Jordan

Pipeline

DoMore Diagnostics is dedicated to expanding our potential and impact on improving cancer patients’ lives. We are actively pursuing further development and advancing our product portfolio for better outcome prediction and personalized cancer treatment.

Intellectual Property

DoMore Diagnostics has secured a global, exclusive license to the patents and patent applications covering the inventions.